In 1911, Peyton Rous made a groundbreaking discovery. He found that a fluid from a chicken’s cancer spread the disease to other chickens. This was a key moment in understanding how cancer grows.1 This discovery started the study of tumor viruses. It led to finding oncogenes – genes that help cancer grow.1 Rous found the Rous sarcoma virus (RSV). It was the first time a virus was known to cause cancer. His work showed that viruses also could lead to cancer, not just other causes.
Rous changed the game by proving RSV could make tumors. Before his finding, people thought cancer only came from non-infectious sources.2 This find pushed research forward. It started the study of tumor viruses. Rous’s work also helped find other cancer-causing viruses, like the Epstein-Barr virus. He also showed how some genes could make cells grow too much, causing cancer.21
Key Takeaways
- Peyton Rous’s 1911 discovery of the Rous sarcoma virus (RSV) was a groundbreaking achievement that opened the field of tumor virology.
- The demonstration that a viral agent could induce malignant tumors challenged the prevailing belief that cancers were solely caused by non-infectious factors.
- Rous’s work laid the foundation for the identification of oncogenes, cellular genes that can drive uncontrolled cell growth and cancer development.
- The discovery of RSV paved the way for the recognition of numerous other tumor-inducing viruses across various species.
- Rous’s pioneering research has had a lasting impact on the field of cancer biology and therapeutics.
The Pioneering Discovery of Rous Sarcoma Virus
In 1911, at The Rockefeller Institute, American pathologist Peyton Rous made a landmark discovery.3 He found the first infectious cause of cancer, the Rous sarcoma virus (RSV). This discovery started a new chapter in the study of cancer.1 Rous’s interest sparked when a woman showed him a chicken with a big tumor. He learned that this tumor could spread to other chickens of the same kind but not to mixed breed chickens, pigeons, or guinea pigs.
Rous was curious. He found out that this tumor could pass to other chickens even without including live cells. This meant a “transmissible agent” was at play, changing how people understood cancer.
Peyton Rous’s Groundbreaking Experiment
What Rous discovered became a major step forward in cancer study.3 He found a virus that could make a healthy animal develop cancer when it infects it. This was a big change from the idea that cancer can’t spread like a cold or the flu.1 His find was the first step in a journey that led to discovering other viruses that can cause tumors in animals. This even included the first human virus known to cause cancer, the Epstein-Barr virus found in 1964.
Rous’s work also helped find genes that, when they don’t work right, can start cancer. This research was key in understanding how cancers can begin on a cellular level.
The Transformative Impact of the Virus Discovery
Rous’s discovery changed everything in cancer research. It proved that some cancers can spread like a disease between animals, and from animals to humans. This was a big deal, challenging common thought.1 It led to finding more viruses like RSV that can cause cancer in different animals, and eventually to the first human virus that causes cancer, the Epstein-Barr virus.3 Also, by finding that the RSV virus had a gene that could cause cancer in its host, Rous set the foundation. He made it possible to find that our genes can sometimes lead to cancer too, which is a big part of what we know about cancer today. This work shaped our deep understanding of how cancer starts and grows, and it keeps influencing cancer studies and treatment methods.
Rous Sarcoma Virus and Cancer
The Rous sarcoma virus (RSV) discovery marked a big step in cancer understanding. It showed that RSV carried an RNA genome. This made RSV the first known retrovirus. The term ‘retrovirus’ came after reverse transcription revelation by Howard Temin and David Baltimore.1 Reverse transcription plays a vital role. It lets the virus’ genetic material stick into the host’s DNA.
Oncogenes: The Key to Unraveling Cancer Mechanisms
Finding the src oncogene was crucial for understanding cancer at a molecular level. The src gene encoded a viral protein with tyrosine kinase activity. This led to the discovery of proto-oncogenes. Proto-oncogenes are normal cells that can turn cancerous by mimicking viral behavior.1 We discovered many more oncogenes after that. These oncogenes control how cells grow and stay alive. Understanding them is key to modern cancer research.
| Src Family Kinase Members | Cancer Associations |
|---|---|
| 11 distinct members identified in humans4 | Elevated Lyn kinase activity in glioblastoma and prostate cancer4 |
| c-Src, the prototypical Src family member | Frequently deregulated in a wide range of human cancers |
| Lyn kinase, another Src family member | Implicated in imatinib resistance in chronic myelogenous leukemia4 |
From c-Src to v-Src: Unveiling the Viral Oncogene
The src gene in the RSV genome. It’s called v-src is the main factor behind the virus’s transformative nature.4 This v-src gene makes a protein that triggers cancer-like changes in some cells because it has tyrosine kinase activity. After more studying, scientists found out that v-src is actually a changed form of c-src, a normal cell gene. This c-src gene usually helps control cell growth and signaling.4 Knowing that c-src is the natural version of v-src was a big discovery. It’s why we now refer to normal cell genes that can fuel cancer as “proto-oncogenes.”
Proto-oncogenes are genes that go off track, leading to cancer.4 The differences in how v-src and c-src work, specifically in their controlling parts, show why the virus’s gene is better at causing cancer. This is because it has more power to change cell behavior.
The Src Family Kinases: Drivers of Cancer Progression
The Src family kinases (SFKs), led by c-Src, play a vital role in advancing cancer. They are especially active in various human cancers, like those in the colon, breast, and more. Despite rare genetic mutations, higher Src protein levels and activity are common in cancer.5 The way Src signals can get out of control varies, but it often involves continuous activation of its function due to certain events.
Elevated Src Kinase Activity in Human Cancers
Besides c-Src, Lyn and others from the Src family are also key in cancer development. Lyn kinase, for example, is too much active in blood cancers like B-CLL and AML. In B-CLL, too much Lyn stops leukemia cells from dying, while in AML, it’s linked to Flt3 mutations.6 Lyn also helps cause drug resistance in some cancers, showing it could be a critical target for treatment.
Lyn Kinase: A Key Player in Solid and Hematological Malignancies
The SFKs are essential for moving cancer forward in different scenarios, studies have shown. They change how cells behave in cancer, which impacts how likely a tumor is to spread. The role Src plays is significant in human cancer outcomes.7 Drugs that can stop Src from working are seen as hopeful treatments for cancer.7 There is a lot of work on finding signs and drug targets that connect to Src function in cancer.
The Road to Nobel Recognition
In 1911, Peyton Rous found the Rous sarcoma virus. This discovery was not noticed much for many years. People were not sure a virus could really cause solid tumors in birds.2
So, the scientific world was slow to accept his work. Yet, Rous kept going. He added a lot to our knowledge of tumor virology over his career at The Rockefeller Institute.2
Decades later, this work helped explain how viruses cause cancer and find genes linked to it. The Nobel Prize in Physiology or Medicine went to him in 1966, when he was 87.2
Peyton Rous’s Lifetime Achievements
Rous’s finding of a virus leading to tumors changed cancer research deeply. It showed that cancers could come from something that spreads, challenging old ideas.8
His study led to finding many more viruses that could cause cancer in animals. The first human cancer virus, Epstein-Barr, was also discovered after Rous’s work.2
Even more, he found a gene in the virus (the src oncogene) that was key to understanding how normal cells turn into cancer cells. This work has been crucial for how we understand and treat cancer today.9
It led to lasting changes in cancer biology and therapies. Rous’s research is still a big part of the study of cancer today.2
The Impact of Rous’s Discovery on Cancer Research
Rous’s discovery about the Rous sarcoma virus deeply affected the study of cancer. It opened a new area of research, showing that some cancers can spread from an agent. This idea was new and challenged what was commonly believed.2
This breakthrough laid the foundation for finding other cancer-causing viruses in different animals. It even led to the discovery of the first cancer-causing virus in humans, Epstein-Barr. This was a huge step forward.2
He also found a gene in the cancer virus that changed our understanding of how cancer starts. His work is fundamental in how we think about cancer and treat it today.9
Rous’s work is still very important in the field of cancer. What he discovered continues to shape cancer research today.2
From RSV to Modern Cancer Therapeutics
Peyton Rous’s work with Rous sarcoma virus (RSV) changed cancer treatment. He found the src oncogene and its v-src counterpart in a virus. This discovery showed that overactive tyrosine kinases play a big role in cancer.2 Now, we have drugs that block these kinases, known as tyrosine kinase inhibitors. These drugs have become key in fighting many cancers. It all started with Rous’s early work.2
Targeted Therapies and Tyrosine Kinase Inhibitors
Rous’s findings opened the door to precise cancer treatments.2 Imatinib was the first drug to target a specific oncogene, the ABL protein. It works well against chronic myelogenous leukemia.2 Big cancer studies show us many oncogenes. They help create new drugs that target specific mutations in cancer.2 Now, we’re looking into even more ways to treat cancer, like Protacs, which may help with hard-to-treat oncogenes.2
Nuclear Export of Viral RNAs
The step of exporting viral RNAs from the nucleus is key in retrovirus replication.10 Retroviruses like Rous sarcoma virus (RSV), HIV-1, HTLV, and MMTV use special proteins to help. These proteins include Rev, Rex, and Rem. They work with a host protein called Crm1 to move the RNAs to the cell’s edge for export. Other host proteins, like Matrin 3 and DDX3, also play a role in making this process smooth in complex retroviruses.
Simple Retroviruses and Host Protein Co-option
In contrast, simple retroviruses such as Rous sarcoma virus don’t make their own export proteins.11 Instead, they use our cell’s proteins, like NFX1/TAP and p15/NXT1. These proteins grab onto specific parts of the viral RNA, CTEs, to guide them through the nucleus. The cellular factor UAP56 and TREX complex proteins help in the export too. This shows how simple retroviruses and the cell’s machinery work together.
Viral Oncogenesis Mechanisms
The Rous sarcoma virus is key in understanding how viruses cause cancer. It showed that a virus could turn normal cells into cancer cells. This happens when the virus carries a changed form of a normal cell gene. This gene change stops the cell from working right, leading to cancer.12 Scientists found that the virus’s gene, called src, came from a normal cell gene, c-src. This discovery was very important. It taught us how these viruses can mess up the cell’s natural ways and cause cancer.12
They learned that the virus’s gene, src, is different from the normal gene, c-src. This difference helps the virus make cells turn into cancer cells more easily. It does this by affecting how the cells work.13 This way of how viruses can lead to cancer is seen in many other viruses too. Because of this, it’s now a big idea when we study cancer caused by viruses.
They found the virus’s gene, src, acts in a special way that’s not like the normal gene, c-src. This special way helps the virus turn cells into cancer cells better.13 This method of virus-made genes changing how our cells work is a big deal in studying virus cancer.
Source Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256973/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961594/
- https://asm.org/articles/2018/october/a-brief-history-of-cancer-virology
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096390/
- https://www.mdpi.com/2072-6694/16/1/32
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486874/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403812/
- https://www.nobelprize.org/prizes/medicine/1966/ceremony-speech/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687565/
- https://www.mdpi.com/1422-0067/24/16/12593
- https://grantome.com/grant/NIH/F31-CA171862-04
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822580/
- https://perspectivesinmedicine.cshlp.org/content/12/4/a035865.full
